<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874350</url>
  </required_header>
  <id_info>
    <org_study_id>LPCN 1148-21-001</org_study_id>
    <nct_id>NCT04874350</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia</brief_title>
  <official_title>A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lipocine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lipocine Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety,&#xD;
      and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 52-week, multicenter, double-blind, placebo-controlled, two arm study of LPCN 1148&#xD;
      in adult men with cirrhosis of the liver and sarcopenia on the liver transplant waitlist.&#xD;
      This study will evaluate the efficacy, safety, and tolerability of LPCN 1148, determined&#xD;
      through a range of clinical outcomes and functional and laboratory tests.&#xD;
&#xD;
      Approximately 60 subjects will be randomized 1:1 ratio to receive one of the following&#xD;
      treatments:&#xD;
&#xD;
        -  Treatment A: Oral LPCN 1148&#xD;
&#xD;
        -  Treatment B: Oral matching placebo.&#xD;
&#xD;
      Subjects will undergo a screening period to determine study eligibility. Adult male subjects&#xD;
      with liver cirrhosis and sarcopenia on the transplant list will be enrolled into the study.&#xD;
&#xD;
      There are two treatment phases to this study.&#xD;
&#xD;
        -  Stage 1: 24 weeks of blinded study treatment (LPCN 1148 or matching placebo&#xD;
&#xD;
        -  Stage 2: 28-week open-label extension. Subjects who participate in Stage 1 of this trial&#xD;
           will roll over to a 28-week open-label extension phase. All subjects will receive LPCN&#xD;
           1148; there will be no placebo in the extension period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1 to LPCN 1148 or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Skeletal Muscle Index in LPCN 1148 treated subjects compared to placebo</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Liver Frailty Index in LPCN 1148 treated subjects compared to placebo</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of waitlist events in LPCN 1148 treated subjects compared to placebo</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>LPCN 1148</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral LPCN 1148 capsules, administered as BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral matching placebo capsules, administered as BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LPCN 1148</intervention_name>
    <description>LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.</description>
    <arm_group_label>LPCN 1148</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral matching placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male â‰¥ 18 years old&#xD;
&#xD;
          2. Currently listed, on the liver transplant waitlist for cirrhosis secondary to&#xD;
             Hepatitis B or C infection, Alcoholic Liver Disease (ALD), or Non-Alcoholic&#xD;
             Steatohepatitis (NASH)&#xD;
&#xD;
          3. Evidence of sarcopenia with appropriate cutoff recommended by clinical guidance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suspected or proven hepatocellular carcinoma (HCC)&#xD;
&#xD;
          2. History of current or suspected prostate or breast cancer&#xD;
&#xD;
          3. History of malignancies other than prostate, breast, or HCC, unless successfully&#xD;
             treated with curative intent and believed to be cured (defined as complete remission&#xD;
             lasting at least 5 years)&#xD;
&#xD;
          4. History of uncontrolled or recurrent portal hypertensive bleeding, including&#xD;
             uncontrolled or recurrent bleeding from varices, gastropathy, colopathy, or&#xD;
             hemorrhoidal bleeding.&#xD;
&#xD;
          5. History or current thrombosis (including portal vein thrombosis), thromboembolism, or&#xD;
             treatment for portal vein thrombosis&#xD;
&#xD;
          6. History of hemochromatosis&#xD;
&#xD;
          7. History of hypercoagulable state (e.g. Factor V Leiden deficiency, protein C&#xD;
             deficiency, protein S deficiency, anti-thrombin III deficiency, or the presence of&#xD;
             lupus anticoagulant)&#xD;
&#xD;
          8. Prior history of complications of ascites including:&#xD;
&#xD;
               1. Spontaneous bacterial peritonitis&#xD;
&#xD;
               2. Hepatic hydrothorax&#xD;
&#xD;
          9. MELD score &gt; 25&#xD;
&#xD;
         10. Abnormal lab value in serum chemistry, hematology, or urinalysis that the PI considers&#xD;
             clinically significant, including but not limited to:&#xD;
&#xD;
               1. PSA &gt; 4 ng/mL&#xD;
&#xD;
               2. Polycythemia (Hematocrit &gt;54%) or history of polycythemia&#xD;
&#xD;
               3. ALT or AST &gt; 5x ULN&#xD;
&#xD;
               4. ALP &gt; 1.5x ULN&#xD;
&#xD;
               5. Platelet count &lt; 30,000/mL&#xD;
&#xD;
               6. EGFR &lt; 60 mL/min/1.73 m2&#xD;
&#xD;
               7. Total bilirubin &gt; 3.0 mg/dL&#xD;
&#xD;
               8. Serum albumin &lt; 2.8 g/dL&#xD;
&#xD;
               9. INR &gt; 2.3 or PT prolongation &gt; 6.0 seconds&#xD;
&#xD;
         11. Subjects with PSA between 2.5 ng/mL and 4 ng/mL are excluded only if any of the below&#xD;
             criteria are met at baseline:&#xD;
&#xD;
               1. Hematocrit &gt; 48%&#xD;
&#xD;
               2. I-PSS &gt; 19&#xD;
&#xD;
               3. Any irregularity found on digital rectal examination of the prostate&#xD;
&#xD;
         12. Subjects with PSA &gt; 3 ng/mL are excluded only if any of the below criteria are met at&#xD;
             baseline:&#xD;
&#xD;
               1. Subject is African American&#xD;
&#xD;
               2. Subject has a first-degree relative who has a history of prostate cancer&#xD;
&#xD;
               3. Hematocrit &gt; 48%&#xD;
&#xD;
               4. I-PSS &gt; 19&#xD;
&#xD;
               5. Any irregularity found on digital rectal examination of the prostate&#xD;
&#xD;
         13. Clinically significant abnormal prostate digital rectal examination (DRE) in the&#xD;
             opinion of the PI, with DRE screening initiated at International Prostate Symptom&#xD;
             Score (I-PSS) &gt; 19&#xD;
&#xD;
         14. History of bariatric surgery&#xD;
&#xD;
         15. History of stroke or myocardial infarction within the past 5 years&#xD;
&#xD;
         16. Known positivity for Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
         17. Acute liver failure as the indication for addition to the liver transplant waitlist&#xD;
&#xD;
         18. Estimated life expectancy less than 3 months or expected to undergo liver transplant&#xD;
             within 3 months&#xD;
&#xD;
         19. Known heart failure of New York Heart Association class III or IV&#xD;
&#xD;
         20. Evidence of severe encephalopathy or encephalopathy that is not controlled despite&#xD;
             adequate medical therapy&#xD;
&#xD;
         21. History of prior organ transplant&#xD;
&#xD;
         22. History of Fontan physiology&#xD;
&#xD;
         23. History of pulmonary embolus&#xD;
&#xD;
         24. Porto-pulmonary hypertension&#xD;
&#xD;
         25. Hepatopulmonary syndrome&#xD;
&#xD;
         26. Uncontrolled epilepsy or migraine&#xD;
&#xD;
         27. Active substance abuse or dependency extending to within the previous 6 months&#xD;
&#xD;
         28. History of significant sensitivity or allergy to testosterone, or product excipients.&#xD;
&#xD;
         29. Use of known strong inhibitors (e.g., ketoconazole) or inducers (e.g., dexamethasone,&#xD;
             phenytoin, rifampin, carbamazepine) of cytochrome P450 3A (CYP3A) within 30 days prior&#xD;
             to study drug administration and through the end of the study&#xD;
&#xD;
         30. Subjects who are currently receiving any androgens (testosterone or other androgens or&#xD;
             androgen-containing supplements) and are unwilling to washout prior to screening&#xD;
&#xD;
             a. Washout: 12 weeks following long-acting intramuscular androgen injections; 4 weeks&#xD;
             following topical or buccal androgens; 3 weeks following oral androgens&#xD;
&#xD;
         31. Uncontrolled hypertension (&gt;160/90 mmHg despite treatment)&#xD;
&#xD;
         32. Uncontrolled obstructive sleep apnea&#xD;
&#xD;
         33. Use of any investigational drug within 5 half-lives of the last dose or in the past 6&#xD;
             months prior to Study Day -2 without medical monitor and/or Sponsor approval&#xD;
&#xD;
         34. Subject who is not willing to use adequate contraception for the duration of the study&#xD;
&#xD;
         35. Any other condition, which in the opinion of the investigator would impede compliance&#xD;
             to the study protocol (including diet, exercise, and alcohol abstinence) or hinder&#xD;
             completion of the study&#xD;
&#xD;
         36. Failure to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

